276 related articles for article (PubMed ID: 20825302)
1. Sorafenib-induced destructive thyroiditis.
Iavarone M; Perrino M; Viganò M; Beck-Peccoz P; Fugazzola L
Thyroid; 2010 Sep; 20(9):1043-4. PubMed ID: 20825302
[No Abstract] [Full Text] [Related]
2. Sorafenib induced thyroiditis in two patients with hepatocellular carcinoma.
van Doorn L; Eskens FA; Visser TJ; van der Lugt A; Mathijssen RH; Peeters RP
Thyroid; 2011 Feb; 21(2):197-202. PubMed ID: 21275767
[TBL] [Abstract][Full Text] [Related]
3. [Hepatocellular carcinoma - long-term treatable disease].
Fínek J
Klin Onkol; 2012; 25(4):287-9. PubMed ID: 22920170
[TBL] [Abstract][Full Text] [Related]
4. Target therapy for hepatocellular carcinoma: is sorafenib for everybody?
Daniele B; Di Maio M
J Clin Gastroenterol; 2009; 43(5):389-90. PubMed ID: 19564813
[No Abstract] [Full Text] [Related]
5. Sorafenib-induced severe acute hepatitis in a stable liver transplant recipient.
Herden U; Fischer L; Schäfer H; Nashan B; von Baehr V; Sterneck M
Transplantation; 2010 Jul; 90(1):98-9. PubMed ID: 20606568
[No Abstract] [Full Text] [Related]
6. Sorafenib in advanced hepatocellular carcinoma.
Spinzi G; Paggi S
N Engl J Med; 2008 Dec; 359(23):2497-8; author reply 2498-9. PubMed ID: 19052134
[No Abstract] [Full Text] [Related]
7. Acute hepatitis in a patient with cirrhosis and hepatocellular carcinoma treated with sorafenib.
Llanos L; Bellot P; Zapater P; Pérez-Mateo M; Such J
Am J Gastroenterol; 2009 Jan; 104(1):257-8. PubMed ID: 19098892
[No Abstract] [Full Text] [Related]
8. Sequential therapy with sunitinib and sorafenib in metastatic hepatocellular carcinoma.
Ahn HK; Lee S; Sun JM; Lee J; Park SH; Park JO; Park YS; Kang WK; Lim HY
Invest New Drugs; 2012 Aug; 30(4):1768-72. PubMed ID: 21720741
[No Abstract] [Full Text] [Related]
9. [Recommendations for the management of Sorafenib in patients with hepatocellular carcinoma].
Reig M; Matilla A; Bustamante J; Castells L; de La Mata M; Delgado M; Moreno JM; Forner A; Varela M
Gastroenterol Hepatol; 2010 Dec; 33(10):741-52. PubMed ID: 20851505
[No Abstract] [Full Text] [Related]
10. Sorafenib in hepatocellular carcinoma.
Josephs DH; Ross PJ
Br J Hosp Med (Lond); 2010 Aug; 71(8):451-6. PubMed ID: 20852487
[TBL] [Abstract][Full Text] [Related]
11. Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib.
Alexandrescu DT; McClure R; Farzanmehr H; Dasanu CA
J Clin Oncol; 2008 Aug; 26(24):4047-8. PubMed ID: 18711201
[No Abstract] [Full Text] [Related]
12. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Cheng AL; Kang YK; Chen Z; Tsao CJ; Qin S; Kim JS; Luo R; Feng J; Ye S; Yang TS; Xu J; Sun Y; Liang H; Liu J; Wang J; Tak WY; Pan H; Burock K; Zou J; Voliotis D; Guan Z
Lancet Oncol; 2009 Jan; 10(1):25-34. PubMed ID: 19095497
[TBL] [Abstract][Full Text] [Related]
13. Fatal hemobilia in advanced hepatocellular carcinoma invading biliary tract after treatment with sorafenib and biliary stenting.
Verset G; Maréchal R; Bali MA; Devière J; Van Laethem JL
Ann Oncol; 2010 Jun; 21(6):1381-1382. PubMed ID: 20332137
[No Abstract] [Full Text] [Related]
14. [Use of sorafenib (Nexavar) in the treatment of hepatocellular carcinoma: PRODIGE AFEF recommendations].
Boige V; Barbare JC; Rosmorduc O;
Gastroenterol Clin Biol; 2008 Jan; 32(1 Pt. 1):3-7. PubMed ID: 18341970
[No Abstract] [Full Text] [Related]
15. Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy.
Saab S; McTigue M; Finn RS; Busuttil RW
Exp Clin Transplant; 2010 Dec; 8(4):307-13. PubMed ID: 21143097
[TBL] [Abstract][Full Text] [Related]
16. Hepatocellular carcinoma: sorafenib before liver transplantation?
Braillon A
Hepatology; 2010 Jun; 51(6):2232-3. PubMed ID: 20041410
[No Abstract] [Full Text] [Related]
17. Complete histologic response induced by sorafenib in advanced hepatocellular carcinoma: a case report.
Curtit E; Thiery-Vuillemin A; Nguyen T; Heyd B; Pivot X; Di Martino V; Borg C
J Clin Oncol; 2011 Apr; 29(12):e330-2. PubMed ID: 21263091
[No Abstract] [Full Text] [Related]
18. Sorafenib for liver cancer: the horizon broadens.
Johnson P; Billingham L
Lancet Oncol; 2009 Jan; 10(1):4-5. PubMed ID: 19111238
[No Abstract] [Full Text] [Related]
19. Invasive squamous cell carcinoma and sorafenib in a black patient.
Donaldson MR; Stetson CL; Smith JL
Arch Dermatol; 2011 Jan; 147(1):133-4. PubMed ID: 21242415
[No Abstract] [Full Text] [Related]
20. Drug therapy: sorafenib.
Finn RS
Hepatology; 2010 May; 51(5):1843-9. PubMed ID: 20432260
[No Abstract] [Full Text] [Related]
[Next] [New Search]